<DOC>
	<DOCNO>NCT00033410</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Tirapazamine may make tumor cell sensitive radiation therapy . Combining chemotherapy , radiation therapy , tirapazamine may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine chemotherapy tirapazamine radiation therapy treat patient stage II stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy , Tirapazamine , Radiation Therapy Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose tirapazamine administer paclitaxel , carboplatin , concurrent radiotherapy patient stage IIB-IIIB non-small cell lung cancer . - Determine , preliminarily , response rate survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter , dose-escalation study tirapazamine . Patients receive induction chemotherapy comprise tirapazamine IV 2 hour carboplatin IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 paclitaxel IV 1 hour day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 , 29 , 32 , 36 , 39 . Beginning day 1 , patient undergo radiotherapy daily 5 day week 6.5 week . Beginning 4-5 week completion radiotherapy , patient stable respond disease receive consolidation chemotherapy comprise paclitaxel IV 3 hour carboplatin IV 30 minute day 1 22 . Cohorts 3-6 patient receive escalate dos tirapazamine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : Approximately 3-30 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary bronchogenic nonsmall cell lung cancer Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Stage IIIA IIIB disease ( T14 , N23 ) Mediastinal lymph node least 2 cm diameter radiography sufficient stage N23 ( must node positive [ cytologically histologically confirm ] large mediastinal node less 2 cm diameter ) OR Selected stage IIB disease ( T3 , N0 T3 , N1 medical condition precludes surgery ) No malignant pleural effusion Measurable evaluable disease chest xray CT scan No metastatic disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 OR ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Platelet count normal Hepatic : Not specify Renal : Creatinine clearance least 60 mL/min Cardiovascular : No uncontrolled congestive heart failure No unstable angina No unstable cardiac arrhythmia Pulmonary : FEV_1 least 1.0 L Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No clinically significant hearing loss PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy lung cancer Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy lung cancer Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
</DOC>